期刊文献+

放疗联合化疗及瘤内注射EIB缺失腺病毒(H101)综合治疗鼻咽癌的临床研究 被引量:4

Radiotherapy combined with chemotherapy and intratumoral injection of EIB gene-deleted adenovirus(H101) for nasopharyngeal carcinoma
下载PDF
导出
摘要 目的:观察放疗联合化疗及瘤内注射EIB缺失腺病毒(H101)综合治疗鼻咽癌的近期疗效和不良反应。方法:符合入选标准的56例鼻咽癌患者先行化疗和同期颈部肿瘤瘤内注射H101,每天1次,每次1支(5×10^11病毒颗粒数/0.5mL),连续5天,化疗用PF方案(DDP20mg/m^2静滴,d1~d5,5-FU500mg/m^2静滴,d1~d5),21天为1疗程。连续2疗程后进行放疗。结果:56例鼻咽癌患者放疗结束时肿瘤消退率为71.4%,好转率为28.6%。放疗后3个月肿瘤消退率为100%。放疗后6个月有2例颈部肿瘤复发。不良反应为注射部位局部疼痛19.6%,非感染性发热41.7%,流感样症状8.9%,白细胞下降42.9%,恶心呕吐33.9%,口腔黏膜损害100%。结论:放疗联合化疗及基因治疗鼻咽癌有明确的近期疗效,毒副反应轻,可望成为鼻咽癌新的综合治疗模式,远期疗效有待进一步观察。 Objective: To evaluate the short-term effects and toxicities of radiotherapy combined with chemotherapy and intratumoral injection of an EIB gene-deleted adenovirus (H101) in treating patients with nasopharyngeal carcinoma. Methods: A total of 56 patients with nasopharyngeal carcinoma were recruited. They first received chemotherapy based on PF regimen(cisplatin 20 mg/m^2 ivgtt,qd×5 d;5-fluorouracil 500 mg/m^2 ivgtt, qd×5 d). Cervical intratumoral injection of H101 (5 ×10H viral particle/0.5 mL) was simultaneously administered to patients once daily for 5 consecutive days. Treatment repeated every 3 weeks as 1 cycle. Patients received radiotherapy after they completed 2 cycles of chemotherapy. Results: Among 56 patients, the complete response rate was 71.4% and partial response rate was 28.6% at the end of radiotherapy. The complete response rate was 100% at 3 months after radiotherapy. Recurrence of cervical tumors was found in 2 patients at 6 months after radiotherapy. Main side effects included injection site reaction (19.6 % ), fever independent of infection(41.7 % ), flu-like symptom (8.9 % ), leukopenia (42.9%), nausea and vomiting ( 33.9 % ), and oral cavity mucosal ulcer ( 100% ). Conclusions: The combination of radiotherapy and chemotherapy plus H101 injection possessed a distinct efficacy in patients with nasopharyngeal carcinoma with lower toxicities. It may become a new pattern of comprehensive therapy for nasopharyngeal carcinoma. The long-term effect need to be further investigated.
出处 《肿瘤》 CAS CSCD 北大核心 2006年第5期453-455,共3页 Tumor
基金 广西壮族自治区科技攻关项目(编号:0322025-5)
关键词 鼻咽肿瘤 抗肿瘤联合化疗方案 放射疗法 基因疗法 腺病毒 Nasopharyngeal neoplasms Antineoplastie combined chemotherapy protocols Radiotherapy Gene therapy Adenovirus, human
  • 相关文献

参考文献12

  • 1NEMUNAITIS J,KHURI F,GANLY I,et al.Phase Ⅱ trial of intratumoral administration of ONYX-015,a replication-selective adenovirus,in patients with refractory head and neck cancer[J].J Clin Oncol,2001,19(2):289-298.
  • 2KHURI FR,NEMUNAITIS J,GANLY I,et al.A controlled trial of intratumoral ONYX-015,a selectively-replicating adenovirus,in combination with cisplatin and 5-fluorouvacil in patients with recurrent head and neck cancer[J].Nat Med,2000,6(8):879-885.
  • 3KWONG D,SHAM J,CHOY D.The effect of loco-regional control on distant metastatic dissemination in carcinoma of the nasopharynx:an analysis of 1301 patients[J].Int J Radiat Oncol Biol Phys,1994,30(5):1029-1035.
  • 4洪明晃,闵华庆.鼻咽癌的分层综合治疗[J].中国肿瘤,1997,6(7):16-17. 被引量:18
  • 5AL-SARRAF M,LEBLANC M,GIRI PG,et al.Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer:phase Ⅲ randomized intergroup study[J].J Clin Oncol,1998,16(4):1310-1314.
  • 6马骏,闵华庆,洪明晃.鼻咽癌化疗与放疗的联合应用[M].//闵华庆.鼻咽癌的研究.广州:广东科技出版社,1998:259.
  • 7BISCHOFF JR,KIRN DH,WILLIAMS A,et al.An adenovirus mutant that replicates selectively in p53-deficient human tumor cells[J].Science,1996,274 (5286):373-376.
  • 8袁中玉,张力,李苏,钱晓洲,管忠震.E1B缺失腺病毒瘤内注射治疗恶性肿瘤的安全性研究[J].癌症,2003,22(3):310-313. 被引量:25
  • 9徐瑞华,袁中玉,管忠震,王华庆,胡晓桦,冯继峰,张阳,李方,陈正堂,王杰军,黄建瑾,周清华,宋三泰.瘤内注射E1B缺失腺病毒治疗恶性肿瘤的Ⅱ期临床研究[J].中国癌症杂志,2004,14(1):12-14. 被引量:11
  • 10徐瑞华,袁中玉,管忠震,曹烨,王华庆,胡晓桦,冯继峰,张阳,李方,陈正堂,王杰军,黄建瑾,周清华,宋三泰.瘤内注射E1B缺失腺病毒(H101)与化疗联合治疗恶性肿瘤的Ⅱ期临床试验[J].癌症,2003,22(12):1307-1310. 被引量:24

二级参考文献27

  • 1[1]Bischoff JR, Kirn DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells[J]. Science,1996,274(5286):373- 376.
  • 2[2]Nemunaitis J, Khuri F, Ganly I, et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer[J]. J Clin Oncol, 2001,19(2):289- 298.
  • 3[3]Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer[J]. Nat Med,2000,6(8):879- 885.
  • 4[4]Ganly I, Eckhardt SG, Rodriguez GI, et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer[J]. Clin Cancer Res,2000,6(3):798- 806.
  • 5[5]Habib NA, Sarraf CE, Mitry RR, et al. E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors[J]. Hum Gene Ther,2001,12(3): 219- 226.
  • 6[6]Mulvihill S, Warren R, Venook A, et al. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial[J]. Gene Ther, 2001, 8(4): 308- 315.
  • 7[7]Heise C,Wukkuans AM,Xue S, et al. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy[J]. Cancer Res, 1999, 59: 2623- 2628.
  • 8[8]Heise C,Ganly I,Kim YT,et al.Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status[J]. Gene Ther, 2000,7:1925- 1929.
  • 9[9]Heise C, Sampson-Johannes A, Williams A, et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents[J]. Nat Med,1997,3(6):639- 645.
  • 10[10]Rogulski KR, Freytag SO, Zhang K, et al. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy[J]. Cancer Res, 2000,60(5):1193- 1196.

共引文献99

同被引文献40

引证文献4

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部